ResultsIQ

ResultsIQ › Latest results › Anlon Healthcare Limited

Anlon Healthcare Limited Q4 FY26 earnings call summary

NSE: AHCL · BSE: 544497

Earnings call of 3 Jun 2026, summarised by AI from the filing.

Anlon Healthcare guides FY27 revenue at ₹380-400 cr and EBITDA margin 24-25%, after FY26 total income grew 42.98% to ₹172.22 cr.

Key takeaways

  1. Q4 margin dip Q4 PAT ₹11.07 cr vs ₹16.65 cr, on higher operating and development expense and raw material price rise.
  2. Growth drivers New capex, CDMO commercialization, DMF filings, and acquisitions to drive growth.
  3. Key risk Raw material price volatility and geopolitical uncertainty may impact margins.

Original filing on BSE

Anlon Healthcare Limited Q1 FY27 results

As filed: Revenue ₹31.0 cr (−6% year on year), EBITDA ₹7.5 cr (+24% year on year), PAT ₹4.8 cr (+20% year on year), EBITDA margin 24.1% (+590 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹55.4 cr, EBITDA ₹13.9 cr, PAT ₹9.8 cr, EBITDA margin 25.1%. Not scored. No result for the same quarter last year. Share price after the results: +14.3% in 27 days (Nifty 500: +0.6%).
  • Q3 FY26: Revenue ₹35.6 cr, EBITDA ₹12.3 cr, PAT ₹5.2 cr, EBITDA margin 34.7%. Not scored. No result for the same quarter last year. Share price after the results: +0.9% in 30 days (Nifty 500: −6.9%).
  • Q2 FY26: Revenue ₹52.0 cr, EBITDA ₹13.0 cr, PAT ₹9.0 cr, EBITDA margin 25.0%. Not scored. No result for the same quarter last year. Share price after the results: −0.8% in 30 days (Nifty 500: −0.2%).
  • Q1 FY26: Revenue ₹33.0 cr, EBITDA ₹6.0 cr, PAT ₹4.0 cr, EBITDA margin 18.2%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Anlon Healthcare Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.